Depth Analysis Of Oncology Development Strategies Market

1
Oncology Development Strategies - Considerable
commercial potential but specific needs must be
addressed
2
Report Description
The oncology therapeutic area has seen
significant development and advances over the
last decade. However, oncology has one of the
lowest overall clinical success rates of all
therapy areas with only a third of oncology drugs
that get to Phase III proceeding to approval.
There are a number of factors that will affect
the likelihood of success in oncology drug
development and these must be taken into
consideration when designing the clinical
development plan. To Get Complete Details Here _at_
http//www.bigmarketresearch.com/oncology-developm
ent-strategies-considerable-commercial-potential-b
ut-specific-needs-must-be-addressed-market Oncolo
gy clinical trials tend to be more complex than
those in other therapy areas, largely due to the
number of endpoints that can be utilized, the
growing need for adaptive trial design and the
types of patients that are eligible for the
clinical studies. While overall survival is the
gold standard endpoint, achieving this is
challenging for many oncology trials and other
endpoints such as progression-free survival are
frequently used as surrogates.
3
Report Description
The approval of oncology drugs has been
facilitated by regulatory mechanisms that have
been put in place to expedite the process for
drugs with small patient populations or that
address areas of high unmet need. Programs to
allow early access to developmental drugs are
becoming the norm in oncology, largely driven by
the high unmet need and serious nature of the
disease, but also due to a desire to obtain
real-life data. Enquire About Report_at_
http//www.bigmarketresearch.com/report-enquiry/13
2497 The report, Oncology Development
Strategies -Considerable commercial potential but
specific needs must be addressed, was written to
provide support and guidance to companies who are
both new entrants and long time players in the
oncology space. CBR Pharma Insights provides
in-depth analysis on the challenges that exist in
developing new oncology products and launching
them successfully into a challenging health care
climate.
4
Report Description

• Scope
• Oncology clinical trials details including
  endpoints, trial design, biomarkers, access to
  patients, and regional data needs
• Regulatory strategies
• oncology launch strategies

5
Report Description

• Key Reasons to Purchase
• Provides insight into why the development of
  oncology drugs is different compared to other
  therapy areas and the implications for the
  overall process.
• Enables you to understand the regulatory
  mechanisms in place to expedite approval of new
  oncology drugs and how these should be
  incorporated into strategic launch planning.
• Provides in-depth analysis of key aspects of
  oncology clinical trial design, examining the
  merits of different endpoints, alternative trial
  designs and the importance of biomarkers in
  oncology clinical trials and drug development.
• Better understand the key critical requirements
  when planning for a successful oncology launch,
  including the impact of indication sequencing and
  how to address specific pricing and reimbursement
  needs.
• Gain clear and actionable recommendations on
  crucial factors to consider when progressing a
  new oncology drug through clinical testing, the
  regulatory process and launch.

6
Table Of Content

• Executive summary
• Methodology
• Why is oncology different?
• Oncology clinical trials
• Endpoints
• Trial design
• Biomarkers
• Access to patients
• Regional data needs
• Regulatory strategies
• Mechanisms in place that can facilitate oncology
  approvals

7
Table Of Content

• Critical success factors
• Effective oncology launch strategies
• Launch sequencing
• Pricing and reimbursement considerations
• Communication planning
• Launching with immature data
• Appendix
• To Get Table Of Content http//www.bigmarketresea
  rch.com/oncology-development-strategies-considerab
  le-commercial-potential-but-specific-needs-must-be
  -addressed-market

8
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/oncology-developm
ent-strategies-considerable-commercial-potential-b
ut-specific-needs-must-be-addressed-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone]E-MAIL
sales_at_bigmarketresearch.com